These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12946861)

  • 1. Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART).
    Bánhegyi D; Bácsi A; Tóth FD; Prohászka Z; Horváth A; Beck Z; Kónya J; Füst G
    Immunol Lett; 2003 Oct; 89(1):25-30. PubMed ID: 12946861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease.
    Füst G; Tóth FD; Kiss J; Ujhelyi E; Nagy I; Bánhegyi D
    AIDS; 1994 May; 8(5):603-9. PubMed ID: 7914732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
    Ortiz GM; Wellons M; Brancato J; Vo HT; Zinn RL; Clarkson DE; Van Loon K; Bonhoeffer S; Miralles GD; Montefiori D; Bartlett JA; Nixon DF
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13288-93. PubMed ID: 11687611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
    Kim JH; Mascola JR; Ratto-Kim S; VanCott TC; Loomis-Price L; Cox JH; Michael NL; Jagodzinski L; Hawkes C; Mayers D; Gilliam BL; Birx DC; Robb ML
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1021-34. PubMed ID: 11485619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR
    AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
    O'Sullivan CE; Peng R; Cole KS; Montelaro RC; Sturgeon T; Jenson HB; Ling PD
    J Med Virol; 2002 Jul; 67(3):320-6. PubMed ID: 12116021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).
    Morris MK; Katzenstein DA; Israelski D; Zolopa A; Hendry RM; Hanson CV
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):405-15. PubMed ID: 11744827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
    Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
    Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients.
    Yao Y; Luo Y; He Y; Zheng Y; Zhang Q; Zhou H; Zeng S; Chen Z; He B; He M
    AIDS Res Hum Retroviruses; 2013 Apr; 29(4):691-7. PubMed ID: 23151174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
    AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune restoration under HAART in patients chronically infected with HIV-1: diversity of T, B, and NK immune responses.
    Le Guillou-Guillemette H; Renier G; Vielle B; Abgueguen P; Chennebault JM; Lunel F; Payan C
    Viral Immunol; 2006; 19(2):267-76. PubMed ID: 16817769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.
    Di Mascio M; Sereti I; Matthews LT; Natarajan V; Adelsberger J; Lempicki R; Yoder C; Jones E; Chow C; Metcalf JA; Sidorov IA; Dimitrov DS; Polis MA; Kovacs JA
    J Virol; 2006 Mar; 80(6):2665-74. PubMed ID: 16501076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study.
    Johnston AM; Valentine ME; Ottinger J; Baydo R; Gryszowka V; Vavro C; Weinhold K; St Clair M; McKinney RE
    Pediatr Infect Dis J; 2001 Oct; 20(10):941-6. PubMed ID: 11642627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.
    Guadalupe M; Reay E; Sankaran S; Prindiville T; Flamm J; McNeil A; Dandekar S
    J Virol; 2003 Nov; 77(21):11708-17. PubMed ID: 14557656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.